Skin Follicular Lymphoma: Key Symptoms, Diagnosis, and Prognosis

Primary cutaneous follicle center lymphoma (PCFCL) is a slow-growing skin cancer that arises from B cells in the skin and, despite the alarming word “lymphoma,” carries a five-year survival rate around 95%. It belongs to a broader family of primary cutaneous lymphomas, meaning the disease starts and remains in the skin rather than spreading from lymph nodes elsewhere in the body. The distinction between a skin-origin lymphoma and one that has spread to the skin from inside the body is critical because it changes nearly everything about how the disease behaves and how it is treated.

What PCFCL Looks Like on the Skin

The most common presentation is one or more slow-growing, reddish or pinkish bumps. These lesions typically appear as erythematous nodules or plaques on the head, neck, or back, though they can show up elsewhere.¹ A single bump on the forehead or scalp that grows over months and does not respond to antibiotics or topical treatments is a classic scenario that eventually leads a dermatologist to biopsy.

The lesions are usually painless and non-itchy, which is part of the reason many patients live with them for months or even years before seeking evaluation. They can be mistaken for cysts, insect bites, or stubborn acne. The color ranges from skin-toned to deep red or violaceous, and textures can vary from smooth dome-shaped nodules to flatter, slightly scaly plaques. Unlike many inflammatory skin conditions, these bumps do not come and go; they persist and slowly enlarge. In rare cases, multiple lesions cluster in the same region, creating what some clinicians describe as a “grouped” pattern on the scalp or trunk.

Who Gets It

PCFCL is uncommon overall but is one of the more frequently diagnosed subtypes of primary cutaneous B-cell lymphoma. A national cohort study identified 1,293 patients over its study period, finding that about 64% were male and half presented at Stage I. Roughly 84% had no significant underlying health conditions at diagnosis.² A smaller clinicopathologic series reported a near-equal split between men and women, with patient ages ranging from 33 to 88 years and an average age of 64.³ So while the disease leans male and tends to appear in middle-aged to older adults, it is not exclusive to any narrow demographic.

How It Is Diagnosed

A skin biopsy is the essential first step. No amount of clinical inspection alone can confirm PCFCL because the lesions look too similar to benign conditions and other lymphoma subtypes. Once tissue is obtained, pathologists examine the cell architecture under a microscope. PCFCL characteristically shows abnormal lymphocyte morphology with monotonous cleaved cells called centrocytes, and sometimes larger cells with vesicular chromatin and multiple nucleoli called centroblasts.⁴ The pattern can be follicular (cells arranged in structures resembling normal lymph node follicles) or diffuse (cells spread out without that follicular architecture). Both patterns are PCFCL; the distinction matters for research but usually does not change treatment decisions.

Immunohistochemistry and Molecular Markers

After the basic microscopic assessment, pathologists run immunohistochemical stains to identify proteins on the surface of the tumor cells. In PCFCL, the cells almost always express Bcl-6 and CD10. One study found CD10 expression in about 91% and Bcl-6 expression in about 97% of cases.⁵ Bcl-2, a protein associated with resistance to cell death, showed up in roughly 41% of cases in the same study. This is a critical point because Bcl-2 expression is much more prominent in systemic follicular lymphoma that has spread to the skin from lymph nodes. When Bcl-2 staining is strong and CD10 is strongly positive, pathologists start suspecting that the skin lesion is secondary rather than primary.⁶

The molecular distinction goes deeper. Systemic follicular lymphoma almost always carries a specific chromosomal rearrangement known as t(14;18), which drives overproduction of Bcl-2. Research using sensitive techniques like fluorescence in situ hybridization has shown that the actual tumor cells in PCFCL do not carry this rearrangement. When traces of t(14;18) are detected in biopsy material, they appear to come from bystander B cells circulating in the blood rather than from the cancer itself.⁷ This means PCFCL is a biologically different disease from the follicular lymphoma that oncologists usually encounter in lymph nodes, even though they share a name and some microscopic features.

Dermoscopy

Before the biopsy needle comes out, dermatologists sometimes use dermoscopy, a technique involving a handheld magnifying device with polarized light, to look at the lesion’s surface and vascular patterns. In primary cutaneous B-cell lymphomas, the most frequent dermoscopic finding is a salmon-colored background (seen in about 79% of images) along with prominent blood vessels (about 78%), typically with a serpentine or irregularly linear pattern.⁸ These features do not clinch the diagnosis by themselves, but they help a skilled dermatologist move cutaneous lymphoma higher on the list of possibilities and push for biopsy rather than watchful waiting.

Telling PCFCL Apart from Mimics

One of the most common diagnostic pitfalls is confusing PCFCL with cutaneous lymphoid hyperplasia, a benign reactive condition that can look nearly identical under the microscope. The key differences are structural: in PCFCL, germinal centers either are absent (in the diffuse type) or look abnormal, with a monotonous appearance, no clear zonation, a reduced or absent mantle zone, and no tingible body macrophages. Aberrant expression of BCL-2 and BCL-6 further separates the malignant process from the benign one.⁴ Clinically, the differential also includes epidermal cysts, arthropod bite reactions, and other cutaneous tumors, all of which are far more common than lymphoma and therefore get considered first.

Distinguishing primary skin disease from secondary skin involvement by a systemic follicular lymphoma is equally important. A patient whose skin biopsy shows strong Bcl-2 staining and t(14;18) positivity warrants thorough systemic workup because the treatment and prognosis for systemic follicular lymphoma with skin deposits are quite different from those for PCFCL.

Staging and Ruling Out Systemic Disease

Once the biopsy confirms a cutaneous lymphoma, physicians need to establish that the disease is truly limited to the skin. For indolent subtypes like PCFCL, the workup typically includes blood tests and imaging. PET/CT scans using 18F-FDG are recommended for patients with suspected disease outside the skin, aggressive subtypes, or late-stage presentations. The European Society for Medical Oncology strongly recommends PET/CT for aggressive cutaneous lymphomas or those showing signs of spread beyond the skin.⁹ For a single, small PCFCL lesion on the scalp of an otherwise healthy person, imaging may be less extensive, but most centers still perform at least a CT scan to be safe. Bone marrow biopsy is reserved for intermediate or aggressive subtypes.

Treatment Options

PCFCL has an unusual treatment landscape for a lymphoma. Because the disease is indolent and skin-limited, the approaches lean toward local, less toxic therapies rather than full-body chemotherapy.

Radiation Therapy

Radiation directed at the skin lesion is one of the most studied treatments. A study of de-escalated radiotherapy for indolent primary cutaneous B-cell lymphomas reported an overall response rate of 91%, with 75% achieving a complete response. The five-year local control rate was 88%, and at ten years it remained at 84%.¹⁰ These are encouraging numbers, particularly because the radiation doses used were relatively low, reducing the risk of significant side effects. In a separate study looking at long-term outcomes after radiation, 97% of patients reported satisfaction with their treatment, though about 55% noted some moderate cosmetic changes at the treatment site over time.¹¹

Rituximab

Rituximab, an antibody that targets a protein called CD20 on B cells, can be given either as an intravenous infusion or injected directly into the skin lesion. A study examining both routes found that all PCFCL patients treated with some form of rituximab achieved a complete response, the highest rate among the cutaneous B-cell lymphoma subtypes studied.¹² Intralesional injection, where the drug goes directly into the bump, is an attractive option for patients with limited disease because it avoids the systemic side effects of intravenous infusion. The research suggests that intralesional rituximab should be considered before moving to more aggressive therapy in indolent cases.

Observation After Biopsy

One of the more surprising aspects of PCFCL management is that some patients need no treatment at all beyond the initial biopsy. In a real-world multicenter study, three patients with indolent cutaneous B-cell lymphoma (two with PCFCL) experienced complete disappearance of their lesions after the diagnostic biopsy alone, without any further intervention. Among the 13 untreated patients tracked in the study, none experienced disease progression over a median follow-up of about 2.7 years.¹³ This does not mean everyone can simply watch and wait, but it underscores just how indolent some cases are. The biopsy itself can occasionally remove enough of the tumor to trigger regression, likely aided by the immune system’s response to the wound.

Prognosis and the Risk of Transformation

PCFCL is associated with an indolent course and excellent five-year survival rates.¹⁴ Large cohort data put the five-year survival at roughly 95%.¹⁵ Recurrence at or near the original site is not uncommon, but recurrences tend to respond well to the same local treatments. The disease can, however, progress to secondary systemic involvement if left untreated for extended periods, which is why even a watch-and-wait strategy includes regular follow-up visits and imaging if symptoms change.

Rarely, PCFCL can transform into diffuse large B-cell lymphoma, a high-grade cancer with a much more aggressive trajectory and a poor prognosis. This transformation has been documented in case reports, but the incidence, optimal management, and long-term outcomes remain poorly characterized.¹⁵ Transformation is something clinicians watch for by monitoring any sudden acceleration in lesion growth, new systemic symptoms like unexplained fevers, night sweats, or weight loss, or the appearance of enlarged lymph nodes beyond the skin.

Factors Linked to Worse Outcomes

While the overall prognosis is favorable, certain groups face higher risk. In the large national cohort study, female sex, older age, higher comorbidity scores, more advanced stage (Stage II or III), and not receiving primary radiation therapy were all associated with lower survival.² The association between female sex and worse outcomes is unexpected given the disease’s male predominance, and the reasons for it are not yet well understood. Older age and existing health problems are more intuitive as prognostic factors, since they affect a person’s ability to tolerate treatment and recover from disease complications.

Living With PCFCL and Quality of Life

A cancer diagnosis that involves visible skin lesions brings unique psychological and social challenges. Research into health-related quality of life in cutaneous lymphoma patients has found that the burden extends well beyond the physical symptoms. Patients report intractable itch, pain, and discomfort, alongside socially stigmatizing cosmetic changes that can erode self-esteem and strain relationships.¹⁶ For PCFCL specifically, the lesions often sit on the head or face, making them hard to conceal. Even after successful treatment, residual cosmetic changes from radiation or scarring from biopsy can be a source of ongoing distress.

The emotional weight of carrying a lymphoma diagnosis also deserves mention. Many patients find it difficult to reconcile the word “lymphoma” with a disease that their doctor describes as indolent and treatable. Anxiety about recurrence or transformation can persist long after the lesion has cleared, and the need for ongoing surveillance visits serves as a recurring reminder. Support groups and dermatology-oncology teams that include mental health professionals can make a meaningful difference for patients navigating this tension between a serious-sounding diagnosis and a genuinely favorable prognosis.

How the Classification Has Evolved

PCFCL has not always been recognized as a distinct entity. For decades, skin lymphomas were lumped together with their systemic counterparts, which led to overtreatment. A patient with a slow-growing bump on the scalp would sometimes receive the same aggressive chemotherapy regimens designed for widespread nodal follicular lymphoma, exposing them to serious side effects for a disease that might have responded to a small dose of radiation. The 2005 WHO-EORTC consensus classification was a turning point, formally separating primary cutaneous lymphomas into their own diagnostic categories based on their clinical behavior and biology rather than just their microscopic appearance.¹⁷ An updated version published in 2018 refined these categories further. The practical result for patients is that PCFCL now reliably gets treated as the indolent skin disease it is rather than as a watered-down version of systemic lymphoma.

This classification shift also highlighted the importance of the molecular differences discussed earlier, particularly the absence of t(14;18) in PCFCL tumor cells. Without that formal reclassification, the default assumption for any follicular lymphoma in the skin would remain systemic disease with skin involvement, leading to unnecessary bone marrow biopsies, aggressive chemotherapy, and substantial anxiety for patients whose actual risk is low. The evolving classification is a case where getting the taxonomy right has direct, tangible consequences for how people are treated and how they feel about their diagnosis.